PrecisionLife is an AI precision medicine company that has developed a radical new approach to complex disease analysis based on patients’ genomic and clinical data.
We use our powerful precisionlife multi-omic analysis platform to screen genomic, phenotypic and patient health datasets, providing unique insights into the signatures driving complex diseases.
We rapidly identify novel targets, biomarkers and drug candidates enabling the discovery and delivery of precision medicines.
We have shown that these disease signatures can lead us to validated targets, drug discovery opportunities and better personalized medicine.
COVID-19
The precisionlife platform can analyse large scale, complex multi-omic and epidemiological data to generate disease insights that are not possible with current tools.
We can turn our analyses around within hours even for significant populations and routinely work with very large anonymized patient datasets.
These capabilities have proved to be extrememely valuable in analyzing the COVID-19 patient datasets currently being generated.
Since undertaking our research into COVID-19, we have identified 59 re-purposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate of patients who develop sepsis while suffering from severe COVID-19.
Our technology has also now enabled us to identify 68 risk-associated genes from analysis of hospitalized COVID-19 patients suggesting opportunities for genomic biomarkers and new treatment options.
Fast, Scalable Innovation Engine
We’ve developed a rapid, scalable pipeline that generates validated targets, candidates & patient stratification biomarkers meeting the 5Rs principles of good pharmaceutical programs
Disease Gallery
We’ve identified and validated targets with potential lead candidates and precision medicine biomarkers for multiple diseases including those below.
ALS
Asthma
Alzheimer’s
Breast Cancer
Licensing and Partnering
We operate an early-stage partnering model to develop and out-license in vitro/in vivo validated assets with comprehensive supporting biological data packages to pharma and biotech partners.
We’re building a TargetBank™ containing partner-ready assets with biological data packages demonstrating their R&D, clinical and commercial disease relevance.
Interested in licensing or partnering?
68 risk-associated genes identified from analysis of hospitalized COVID-19 patients suggesting opportunities for genomic biomarkers and new treatment options
PrecisionLife's unique AI platform has found 68 genes associated with risk of developing severe COVID-19 after analysis of the genomes of 929 patients from the UK Biobank who had a severe response...
Shared sepsis / severe COVID-19 genetic risk factors with 59 potential drug re-purposing candidates identified in fight against COVID-19
Using PrecisionLife's proprietary AI enabled precision medicine platform we have identified 59 re-purposing drug candidates that could be used to develop new therapeutic strategies to increase the...
Tackling Coronavirus with Digital Technologies – Virtual Conference and Networking Event, Wednesday 8th April, 2020, from 2pm
PrecisionLife CEO & Founder Dr Steve Gardner will be taking part in an expert panel discussion at a Virtual Conference and Networking Event looking at ‘Digital Medicine Solutions for COVID-19’...
Carbon Neutral
We are proud to be certified carbon neutral, achieved by proactively reducing our carbon footprint and offsetting our remaining carbon emissions. We chose the Climate Care BURN Stoves project, which won the 2015 Ashden International Clean Energy for Women and Girls Award.
Equality and Diversity
We are an equal opportunities employer. We are committed to ensuring that no employee or prospective employee receives less favourable treatment on the grounds of gender, sexual orientation, marital status, disability, race, colour or national origin.
Information Security
precisionlife is proud to hold ISO27001:2013 accreditation. Our partners and users can be confident in our information security processes.
